Arcus Biosciences (RCUS) Invested Capital (2016 - 2026)

Arcus Biosciences' Invested Capital history runs 11 years deep, the most recent figure standing at $624.0 million for Q1 2026.

• In Q1 2026, Invested Capital rose 7.77% year-over-year to $624.0 million; the TTM figure through Mar 2026 stood at $624.0 million (up 7.77% YoY), while the FY2025 annual figure was $730.0 million, up 36.96% from the prior year.
• Invested Capital was $624.0 million for Q1 2026 at Arcus Biosciences, down from $730.0 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $797.0 million in Q1 2022 to a low of $462.0 million in Q4 2023.
• Historically, Invested Capital has averaged $626.4 million across 5 years, with a median of $624.0 million in 2026.
• The sharpest annual moves came in 2023 and 2025: Invested Capital retreated 29.68% in 2023, then jumped 36.96% in 2025.
• A 5-year view of Invested Capital shows it stood at $657.0 million in 2022, then fell by 29.68% to $462.0 million in 2023, then gained by 15.37% to $533.0 million in 2024, then surged by 36.96% to $730.0 million in 2025, then dropped by 14.52% to $624.0 million in 2026.
• The last three Invested Capital figures came in at $624.0 million (Q1 2026), $730.0 million (Q4 2025), and $534.0 million (Q3 2025), per Business Quant data.